BACKGROUND: Activation of bypass signaling pathways, impairment of apoptosis and mutation of epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms of resistance to single-agent erlotinib therapy in non-small-cell lung cancer (NSCLC) driven by EGFR mutations. Orphan receptor 1 (ROR1) knockdown inhibited the growth of NCI-H1975 cells (harboring EGFR L858R and T790M mutations). A pro-survival function for ROR1/MEK/ERK signaling in cooperation with AKT has been demonstrated. METHODS: We have assessed ROR1 expression in 45 patients from the EURTAC trial (clinicaltrials.gov NCT00446225), 27 of whom harbored pretreatment concomitant EGFR T790M mutations, and correlated results with outcome. RESULTS: Progression-free survival (PFS) was 11.8 months for erlotinib-treated patients with low/intermediate and 5.8 months for those with high ROR1 levels. PFS for chemotherapy-treated patients was 5.6 and 9 months, respectively (P=0.0165). A total of 15 erlotinib-treated patients harbored concomitant T790M mutations; for these patients, PFS was 10.8 months for those with low/intermediate compared to 2.7 months for those with high ROR1 levels. In contrast, among 12 chemotherapy-treated patients with concomitant T790M mutations, PFS was 5.8 months for those with low/intermediate, compared to 14.2 months for those with high ROR1 levels (P=0.0138). CONCLUSIONS: ROR1 expression has a differential effect on outcome to erlotinib and chemotherapy in EGFR-mutant NSCLC patients. High ROR1 expression significantly limits PFS in erlotinib-treated patients with T790M mutations and ROR1-directed therapies can enhance the efficacy of treatment. In contrast, high ROR1 expression confers longer PFS to chemotherapy in the same group of patients. The role of chemotherapy and erlotinib in EGFR-mutant NSCLC patients with high ROR1 expression warrants further investigation.
BACKGROUND: Activation of bypass signaling pathways, impairment of apoptosis and mutation of epidermal growth factor receptor (EGFR) to a drug-resistant state are well known mechanisms of resistance to single-agent erlotinib therapy in non-small-cell lung cancer (NSCLC) driven by EGFR mutations. Orphan receptor 1 (ROR1) knockdown inhibited the growth of NCI-H1975 cells (harboring EGFRL858R and T790M mutations). A pro-survival function for ROR1/MEK/ERK signaling in cooperation with AKT has been demonstrated. METHODS: We have assessed ROR1 expression in 45 patients from the EURTAC trial (clinicaltrials.gov NCT00446225), 27 of whom harbored pretreatment concomitant EGFRT790M mutations, and correlated results with outcome. RESULTS: Progression-free survival (PFS) was 11.8 months for erlotinib-treated patients with low/intermediate and 5.8 months for those with high ROR1 levels. PFS for chemotherapy-treated patients was 5.6 and 9 months, respectively (P=0.0165). A total of 15 erlotinib-treated patients harbored concomitant T790M mutations; for these patients, PFS was 10.8 months for those with low/intermediate compared to 2.7 months for those with high ROR1 levels. In contrast, among 12 chemotherapy-treated patients with concomitant T790M mutations, PFS was 5.8 months for those with low/intermediate, compared to 14.2 months for those with high ROR1 levels (P=0.0138). CONCLUSIONS:ROR1 expression has a differential effect on outcome to erlotinib and chemotherapy in EGFR-mutant NSCLCpatients. High ROR1 expression significantly limits PFS in erlotinib-treated patients with T790M mutations and ROR1-directed therapies can enhance the efficacy of treatment. In contrast, high ROR1 expression confers longer PFS to chemotherapy in the same group of patients. The role of chemotherapy and erlotinib in EGFR-mutant NSCLCpatients with high ROR1 expression warrants further investigation.
Authors: Rafael Rosell; Miguel Angel Molina; Carlota Costa; Sara Simonetti; Ana Gimenez-Capitan; Jordi Bertran-Alamillo; Clara Mayo; Teresa Moran; Pedro Mendez; Felipe Cardenal; Dolores Isla; Mariano Provencio; Manuel Cobo; Amelia Insa; Rosario Garcia-Campelo; Noemi Reguart; Margarita Majem; Santiago Viteri; Enric Carcereny; Ruth Porta; Bartomeu Massuti; Cristina Queralt; Itziar de Aguirre; Jose Miguel Sanchez; Maria Sanchez-Ronco; Jose Luis Mate; Aurelio Ariza; Susana Benlloch; Jose Javier Sanchez; Trever G Bivona; Charles L Sawyers; Miquel Taron Journal: Clin Cancer Res Date: 2011-01-13 Impact factor: 12.531
Authors: Yiling Lu; Qinghua Yu; Jue Hui Liu; Jinyi Zhang; Hongwei Wang; Dimpy Koul; John S McMurray; Xianjun Fang; W K Alfred Yung; Kathy A Siminovitch; Gordon B Mills Journal: J Biol Chem Date: 2003-07-17 Impact factor: 5.157
Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245
Authors: Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps Journal: Cancer Res Date: 2013-06-15 Impact factor: 12.701
Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal Journal: Nucleic Acids Res Date: 2010-10-15 Impact factor: 16.971
Authors: Ashwini Balakrishnan; Tracy Goodpaster; Julie Randolph-Habecker; Benjamin G Hoffstrom; Florencia G Jalikis; Lisa K Koch; Carolina Berger; Paula L Kosasih; Anusha Rajan; Daniel Sommermeyer; Peggy L Porter; Stanley R Riddell Journal: Clin Cancer Res Date: 2016-11-16 Impact factor: 12.531
Authors: Walter Z Wang; Konstantin Shilo; Joseph M Amann; Alyssa Shulman; Mohammad Hojjat-Farsangi; Håkan Mellstedt; Johan Schultz; Carlo M Croce; David P Carbone Journal: Cell Death Dis Date: 2021-06-04 Impact factor: 8.469
Authors: Chunlai Li; Shouyu Wang; Zhen Xing; Aifu Lin; Ke Liang; Jian Song; Qingsong Hu; Jun Yao; Zhongyuan Chen; Peter K Park; David H Hawke; Jianwei Zhou; Yan Zhou; Shuxing Zhang; Han Liang; Mien-Chie Hung; Gary E Gallick; Leng Han; Chunru Lin; Liuqing Yang Journal: Nat Cell Biol Date: 2017-01-23 Impact factor: 28.824
Authors: Niki Karachaliou; Imane Chaib; Andres Felipe Cardona; Jordi Berenguer; Jillian Wilhelmina Paulina Bracht; Jie Yang; Xueting Cai; Zhigang Wang; Chunping Hu; Ana Drozdowskyj; Carles Codony Servat; Jordi Codony Servat; Masaoki Ito; Ilaria Attili; Erika Aldeguer; Ana Gimenez Capitan; July Rodriguez; Leonardo Rojas; Santiago Viteri; Miguel Angel Molina-Vila; Sai-Hong Ignatius Ou; Morihito Okada; Tony S Mok; Trever G Bivona; Mayumi Ono; Jean Cui; Santiago Ramón Y Cajal; Alex Frias; Peng Cao; Rafael Rosell Journal: EBioMedicine Date: 2018-02-05 Impact factor: 8.143